Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in May

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 3,480,000 shares, a growth of 446.6% from the May 15th total of 636,700 shares. Currently, 6.7% of the shares of the stock are short sold. Based on an average daily volume of 3,760,000 shares, the short-interest ratio is presently 0.9 days.

Spero Therapeutics Price Performance

Spero Therapeutics stock traded up $0.05 during trading on Thursday, reaching $2.85. 1,747,739 shares of the company were exchanged, compared to its average volume of 2,315,844. The stock's 50 day simple moving average is $1.09 and its two-hundred day simple moving average is $0.97. The company has a market capitalization of $159.35 million, a P/E ratio of 40.72 and a beta of 1.31. Spero Therapeutics has a 52-week low of $0.51 and a 52-week high of $3.06.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.30. The business had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%. As a group, equities analysts forecast that Spero Therapeutics will post -1.2 earnings per share for the current year.

Institutional Investors Weigh In On Spero Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SPRO. Mackenzie Financial Corp grew its stake in shares of Spero Therapeutics by 11.4% in the 1st quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock valued at $151,000 after buying an additional 21,472 shares during the period. Three Seasons Wealth LLC acquired a new position in Spero Therapeutics in the fourth quarter valued at approximately $31,000. XTX Topco Ltd purchased a new position in Spero Therapeutics in the fourth quarter worth approximately $31,000. Virtu Financial LLC acquired a new stake in Spero Therapeutics during the fourth quarter worth $47,000. Finally, Prudential Financial Inc. purchased a new stake in Spero Therapeutics in the fourth quarter valued at $51,000. 25.60% of the stock is currently owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.